Carl Dambkowski, the Chief Medical Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), has recently sold shares of the company worth approximately $139,801. The transactions, executed on April 2, 2025, were carried out under a Rule 10b5-1 trading plan adopted in August 2024. The sale comes as the stock has declined nearly 19% over the past week, with InvestingPro analysis indicating the company is currently undervalued.
The sales involved a total of 3,860 shares of common stock, sold at prices ranging from $35.56 to $37.59 per share. Following these transactions, Dambkowski retains ownership of 247,173 shares in the company. With the stock now trading at $32.32 and analysts setting price targets between $80 and $116, InvestingPro subscribers can access detailed insider trading patterns and 7 additional key insights about APGE’s financial health.
Apogee Therapeutics is a Waltham, Massachusetts-based firm specializing in biological products, with a current market capitalization of $2.03 billion. The sales were conducted in multiple transactions, with specific price details available upon request to the issuer or the Securities and Exchange Commission.
In other recent news, Apogee Therapeutics has entered into a significant manufacturing agreement with Samsung (KS:005930) Biologics for the production of its drug substance, APG777. This agreement outlines the production and supply for clinical development and potential commercial sale, with the Master Services Agreement effective until February 2035. Additionally, Apogee has committed to purchasing minimum quantities of APG777 under an Initial Project Specific Agreement, which will last until December 2034. In analyst updates, TD Cowen reiterated a Buy rating on Apogee Therapeutics, citing promising results from the Phase I APG990 trials and expressing confidence in the upcoming Phase II AD study for APG777. Jefferies also maintained a Buy rating while increasing the stock’s price target to $86, following positive early-stage clinical trial data. The firm highlighted the potential of Apogee’s IL13/OX40L combination therapy and its promising results in the Single Ascending Dose study. These recent developments underscore Apogee’s progress in its clinical programs and strategic partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.